Twin-to-Twin Transfusion Syndrome (TTTS):
Symptoms, Staging, and What Happens Next

If you have been told you are carrying monochorionic twins, TTTS is probably something you have heard about. You may have read terrifying statistics online, or had a care team member mention it in passing without quite finishing the explanation. The anxiety that follows is completely understandable.

This article explains what TTTS actually is, who is at risk, how it is detected and staged, and what treatment looks like. The goal is not to reassure you that everything will be fine, because that is not something any article can promise. The goal is to give you the accurate, complete information you need to understand what your care team is watching for and why.

What is TTTS and why does it only affect some twin pregnancies?

Twin-to-Twin Transfusion Syndrome occurs in monochorionic twin pregnancies, where both babies share a single placenta. Within that shared placenta, blood vessels on its surface connect the two babies' circulations. In most cases those connections are balanced. In TTTS, the balance breaks down: blood flows unequally from one twin (the donor) to the other (the recipient).

The donor twin gradually loses blood volume. As a result, it produces less urine, and the amniotic fluid in its sac decreases. The recipient twin receives too much blood, overloads its heart and kidneys, produces excess urine, and its amniotic fluid increases. Left untreated, this imbalance becomes progressively more dangerous for both twins.

TTTS cannot affect dichorionic twins (DCDA pregnancies), where each baby has a separate placenta. The shared placental circulation is the essential mechanism, so TTTS is only possible in monochorionic pregnancies. According to ISUOG practice guidelines for multiple pregnancy, TTTS develops in approximately 10–15% of monochorionic diamniotic (MCDA) pregnancies. MCMA pregnancies, which share both a placenta and an amniotic sac, are also at risk.

TTTS symptoms: what you will and will not feel

The hardest thing to understand about TTTS is that there are often no symptoms in the early stages that a parent can feel. The condition develops in the amniotic fluid and the fetuses' cardiovascular systems, not in ways that cause obvious maternal sensation.

By the time a parent notices something, TTTS has often already progressed to a significant stage. What you might notice:

• A sudden, rapid increase in the size of your bump
• A feeling of tightness, pressure, or difficulty breathing that comes on quickly
• Discomfort that seems out of proportion to your gestational week
• Reduced movement from one or both babies (though attribution to a specific twin is difficult)

These physical signs reflect the advanced stage at which the fluid imbalance has become large enough to stretch the uterus significantly. At that point, TTTS has already been developing for some time.

That is the whole point of the monitoring schedule. For MCDA pregnancies, detection of TTTS depends on ultrasound, not symptoms. The ultrasound looks for the fluid discordance between the two sacs before it becomes severe. If you miss scans or delay them, you reduce the window for early intervention.

The Quintero staging system: how TTTS is classified

When TTTS is diagnosed on ultrasound, it is classified according to the Quintero staging system, first described by Quintero and colleagues in the Journal of Perinatology (1999) and now the universally accepted classification framework. There are five stages:

The Quintero system guides treatment decisions, but staging does not predict progression in a straight line. Some Stage I cases remain stable; others progress rapidly to Stage III. The system provides a common language for care teams, not a precise timeline for what will happen next.

What the guidelines say about monitoring MCDA pregnancies

NICE guidelines for twin and triplet pregnancy (NG137, 2019) set out the UK care pathway for monochorionic pregnancies explicitly. The recommendation is fortnightly ultrasound monitoring for all uncomplicated MCDA pregnancies from 16 weeks of gestation. This is not a suggestion: it is the evidence-based standard that exists because, as ISUOG practice guidelines document, TTTS most commonly develops between 16 and 26 weeks, and this is the window during which early detection makes the biggest difference.

ISUOG practice guidelines for multiple pregnancy, updated and widely adopted across European and international fetal medicine centres, align with this schedule. The fortnightly scan checks amniotic fluid volumes in both sacs, assesses bladder filling in the donor twin, and reviews Doppler measurements when indicated.

If you are carrying MCDA twins and your care team has not discussed this monitoring schedule with you, raise it at your next appointment. You have the right to know your monitoring plan.

How TTTS is treated

The primary treatment for TTTS from Quintero Stage II onwards is fetoscopic laser photocoagulation of the communicating placental blood vessels. This procedure, performed at a specialist fetal medicine centre under local anaesthetic with sedation, uses a thin telescope (fetoscope) introduced through the mother's abdomen to map and seal the abnormal connecting vessels on the surface of the placenta.

NICE guidelines (NG137, 2019) recommend referral to a specialist fetal medicine centre for all cases of TTTS from Stage II upward, for consideration of laser therapy. Some centres also treat selected Stage I cases where monitoring shows rapid deterioration.

The procedure does not cure TTTS by rebalancing the blood flow: it stops the unequal transfer by eliminating the communicating vessels entirely, effectively separating the two babies' circulations on the same placenta. After successful laser treatment, the two sacs gradually normalise their fluid volumes over subsequent weeks.

Published outcome data from specialist fetal medicine centres, drawn from programmes that have performed laser surgery at scale over many years, consistently show that survival of at least one twin is achieved in the majority of treated pregnancies. Both-twin survival rates vary by stage at diagnosis, gestational age, and the experience of the treating centre. Longer-term follow-up studies have generally shown encouraging neurological outcomes in survivors, with better results at earlier stages and higher-volume centres.

For Stage I TTTS, management may involve close monitoring (sometimes called watchful waiting) with fortnightly or more frequent scans. The decision to intervene at Stage I is individualised and depends on gestational age, rate of progression, and the assessment of an experienced fetal medicine specialist.

What this means for you

If you are carrying MCDA twins and you are reading this before your 16-week scan, the most important thing you can do is confirm your monitoring schedule with your midwife or consultant. You should have a scan every two weeks from 16 weeks onwards. If appointments are being offered at wider intervals than this, ask specifically about the NICE-recommended schedule for monochorionic pregnancies.

If you have been told TTTS has been identified, ask your care team which stage it is, what the plan is, and whether referral to a fetal medicine centre has been arranged or is being considered. You are entitled to a clear explanation of the staging and what the next step is.

If you are at an early stage (Stage I) and being monitored, try not to extrapolate a worst-case trajectory. Some Stage I pregnancies stabilise. Others progress. The scans are how your team stays ahead of it.

Frequently asked questions about TTTS